Introduction: The prevalence of HIV-associated neurocognitive disorders continues to rise despite the widespread use of antiretroviral therapy. We aimed to define the risk of neurocognitive dysfunction among smokers relative to nonsmokers. Methods: We conducted a retrospective cohort study including HIV-infected adults ages 21 to 65 years. https://www.roneverhart.com/Aftermath-Cabernet-Sauvignon-Napa-Valley-2017/